File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Children and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a 'watch and wait' strategy after complete resection

TitleChildren and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a 'watch and wait' strategy after complete resection
Authors
KeywordsMedical sciences
Oncology medical sciences
Pediatrics
Issue Date2013
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/
Citation
The 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 S3, p. 78-79, abstract no. P-0103 How to Cite?
AbstractPURPOSE/OBJECTIVE: Data on clinical features and outcome in pediatric follicular lymphoma (pFL) are scarce. The aim of this retrospective study including 13 EICNHL (European Intergroup for Childhood non-Hodgkin lymphoma) and/or i-BFM (Berlin-Frankfurt-Munster) Study Group members was to assess clinical characteristics and course in a series of 63 pFL patients. MATERIALS AND METHODS: Between May and December 2011, we performed an international survey of pFL including only patients with nationally centrally reviewed histopathology. The survey included questions on demographics [age, gender, sites of involvement, stage of disease, pre-therapeutic lactate dehydrogenase (LDH) level], treatment (surgery, chemotherapy, radiotherapy) and outcome (date of remission, relapse, death, last follow-up). RESULTS: Pediatric FL was found to be associated with male gender (3:1), older age (72% ≥ 10 years old), low serum LDH levels (<500 U/l in 75%), grade 3 histology (in 88%), and limited disease (87% stage I/II disease) mostly involving the peripheral lymph nodes. Forty-four/63 patients received any polychemotherapy and one/63 rituximab only while 17/63 underwent a ‘watch and wait’ strategy. Of 36 stage I patients 30 had complete resections. Only one patient relapsed; 2-year event-free survival and overall survival were 94% +/- 5% and 100%, respectively, after a median follow-up of 2.2 years. CONCLUSIONS: As children with non-resectable pFL had an excellent outcome with multidrug chemotherapy which is associated with acute- and long-term toxicity, multinational controlled trials have to be performed, taking genetics into account, to establish not only that no chemotherapy is a safe approach in stage I patients with complete resection, but low-intensity chemotherapy +/- monoclonal antibodies is sufficient for patients with non-completely resectable disease.
DescriptionThis journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013
Poster Session - Lymphomas: abstract no. P-0103
Persistent Identifierhttp://hdl.handle.net/10722/193639
ISSN
2015 Impact Factor: 2.634
2015 SCImago Journal Rankings: 1.505

 

DC FieldValueLanguage
dc.contributor.authorAttarbaschi, Aen_US
dc.contributor.authorBeishuizen, Aen_US
dc.contributor.authorMann, Gen_US
dc.contributor.authorRosolen, Aen_US
dc.contributor.authorMori, Ten_US
dc.contributor.authorUyttebroeck, Aen_US
dc.contributor.authorNiggli, Fen_US
dc.contributor.authorCsoka, Men_US
dc.contributor.authorKrenova, Zen_US
dc.contributor.authorMellgren, Ken_US
dc.contributor.authorKabickova, Een_US
dc.contributor.authorChiang, Aen_US
dc.contributor.authorReiter, Aen_US
dc.contributor.authorWilliams, Den_US
dc.contributor.authorBurkhardt, Ben_US
dc.date.accessioned2014-01-20T05:12:16Z-
dc.date.available2014-01-20T05:12:16Z-
dc.date.issued2013en_US
dc.identifier.citationThe 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 S3, p. 78-79, abstract no. P-0103en_US
dc.identifier.issn1545-5009-
dc.identifier.urihttp://hdl.handle.net/10722/193639-
dc.descriptionThis journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013-
dc.descriptionPoster Session - Lymphomas: abstract no. P-0103-
dc.description.abstractPURPOSE/OBJECTIVE: Data on clinical features and outcome in pediatric follicular lymphoma (pFL) are scarce. The aim of this retrospective study including 13 EICNHL (European Intergroup for Childhood non-Hodgkin lymphoma) and/or i-BFM (Berlin-Frankfurt-Munster) Study Group members was to assess clinical characteristics and course in a series of 63 pFL patients. MATERIALS AND METHODS: Between May and December 2011, we performed an international survey of pFL including only patients with nationally centrally reviewed histopathology. The survey included questions on demographics [age, gender, sites of involvement, stage of disease, pre-therapeutic lactate dehydrogenase (LDH) level], treatment (surgery, chemotherapy, radiotherapy) and outcome (date of remission, relapse, death, last follow-up). RESULTS: Pediatric FL was found to be associated with male gender (3:1), older age (72% ≥ 10 years old), low serum LDH levels (<500 U/l in 75%), grade 3 histology (in 88%), and limited disease (87% stage I/II disease) mostly involving the peripheral lymph nodes. Forty-four/63 patients received any polychemotherapy and one/63 rituximab only while 17/63 underwent a ‘watch and wait’ strategy. Of 36 stage I patients 30 had complete resections. Only one patient relapsed; 2-year event-free survival and overall survival were 94% +/- 5% and 100%, respectively, after a median follow-up of 2.2 years. CONCLUSIONS: As children with non-resectable pFL had an excellent outcome with multidrug chemotherapy which is associated with acute- and long-term toxicity, multinational controlled trials have to be performed, taking genetics into account, to establish not only that no chemotherapy is a safe approach in stage I patients with complete resection, but low-intensity chemotherapy +/- monoclonal antibodies is sufficient for patients with non-completely resectable disease.-
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/-
dc.relation.ispartofPediatric Blood & Canceren_US
dc.rightsPediatric Blood & Cancer. Copyright © John Wiley & Sons, Inc.-
dc.subjectMedical sciences-
dc.subjectOncology medical sciences-
dc.subjectPediatrics-
dc.titleChildren and adolescents with follicular lymphoma have an excellent prognosis with either limited chemotherapy or with a 'watch and wait' strategy after complete resectionen_US
dc.typeConference_Paperen_US
dc.identifier.emailChiang, A: chiangak@hku.hken_US
dc.identifier.authorityChiang, A=rp00403en_US
dc.identifier.doi10.1002/pbc.24719-
dc.identifier.hkuros227217en_US
dc.identifier.volume60-
dc.identifier.issueS3-
dc.identifier.spage78-
dc.identifier.epage79-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats